1. Ahmad W, Ijaz B, Gull S, Asad S, Khaliq S, Jahan S, et al. A brief review on molecular, genetic and imaging techniques for HCV fibrosis evaluation. Virol J. 2011; 8:53.
Article
2. Parkes J, Guha IN, Harris S, Rosenberg WM, Roderick PJ. Systematic review of the diagnostic performance of serum markers of liver fibrosis in alcoholic liver disease. Comp Hepatol. 2012; 11:5.
Article
3. Poynard T, Halfon P, Castera L, Munteanu M, Imbert-Bismut F, Ratziu V, et al. Standardization of ROC curve areas for diagnostic evaluation of liver fibrosis markers based on prevalences of fibrosis stages. Clin Chem. 2007; 53:1615–22.
Article
4. Schuppan D, Afdhal NH. Liver cirrhosis. Lancet. 2008; 371:838–51.
Article
5. Castera L, Pinzani M. Biopsy and non-invasive methods for the diagnosis of liver fibrosis: does it take two to tango? Gut. 2010; 59:861–6.
Article
6. Theise ND. Liver biopsy assessment in chronic viral hepatitis: a personal, practical approach. Mod Pathol. 2007; 20 Suppl 1:S3–14.
Article
7. Brunt EM. Grading and staging the histopathological lesions of chronic hepatitis: the Knodell histology activity index and beyond. Hepatology. 2000; 31:241–6.
Article
8. Nightingale K. Acoustic radiation force impulse (ARFI) imaging: a review. Curr Med Imaging Rev. 2011; 7:328–39.
Article
9. Haque M, Robinson C, Owen D, Yoshida EM, Harris A. Comparison of acoustic radiation force impulse imaging (ARFI) to liver biopsy histologic scores in the evaluation of chronic liver disease: a pilot study. Ann Hepatol. 2010; 9:289–93.
Article
10. Narimatsu H. Development of M2BPGi: a novel fibrosis serum glyco-biomarker for chronic hepatitis/cirrhosis diagnostics. Expert Rev Proteomics. 2015; 12:683–93.
Article
11. Toshima T, Shirabe K, Ikegami T, Yoshizumi T, Kuno A, Togayachi A, et al. A novel serum marker, glycosylated Wisteria floribunda agglutinin-positive Mac-2 binding protein (WFA(+)-M2BP), for assessing liver fibrosis. J Gastroenterol. 2015; 50:76–84.
Article
12. Tamaki N, Kurosaki M, Loomba R, Izumi N. Clinical utility of Mac-2 binding protein glycosylation isomer in chronic liver diseases. Ann Lab Med. 2021; 41:16–24.
Article
13. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology. 1996; 24:289–93.
Article
14. Li Q, Song J, Huang Y, Li X, Zhuo Q, Li W, et al. The gamma-glutamyl-transpeptidase to platelet ratio does not show advantages than APRI and Fib-4 in diagnosing significant fibrosis and cirrhosis in patients with chronic hepatitis B: a retrospective cohort study in China. Medicine (Baltimore). 2016; 95:e3372.
15. Rosenberg I, Cherayil BJ, Isselbacher KJ, Pillai S. Mac-2-binding glycoproteins: putative ligands for a cytosolic beta-galactoside lectin. J Biol Chem. 1991; 266:18731–6.
Article
16. Kuno A, Ikehara Y, Tanaka Y, Ito K, Matsuda A, Sekiya S, et al. A serum “sweet-doughnut” protein facilitates fibrosis evaluation and therapy assessment in patients with viral hepatitis. Sci Rep. 2013; 3:1065.
Article
17. Yamasaki K, Tateyama M, Abiru S, Komori A, Nagaoka S, Saeki A, et al. Elevated serum levels of Wisteria floribunda agglutinin-positive human Mac-2 binding protein predict the development of hepatocellular carcinoma in hepatitis C patients. Hepatology. 2014; 60:1563–70.
Article
18. Nishikawa H, Enomoto H, Iwata Y, Kishino K, Shimono Y, Hasegawa K, et al. Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein for patients with chronic hepatitis B and C: a comparative study. J Viral Hepat. 2016; 23:977–84.
Article
19. Shigefuku R, Takahashi H, Nakano H, Watanabe T, Matsunaga K, Matsumoto N, et al. Correlations of hepatic hemodynamics, liver function, and fibrosis markers in nonalcoholic fatty liver disease: comparison with chronic hepatitis related to hepatitis C virus. Int J Mol Sci. 2016; 17:1545.
Article
20. Burak Ozkan M, Bilgici MC, Eren E, Caltepe G. Diagnostic accuracy of point shear wave elastography in the detection of portal hypertension in pediatric patients. Diagn Interv Imaging. 2018; 99:151–6.
Article
21. Attia D, Schoenemeier B, Rodt T, Negm AA, Lenzen H, Lankisch TO, et al. Evaluation of liver and spleen stiffness with acoustic radiation force impulse quantification elastography for diagnosing clinically significant portal hypertension. Ultraschall Med. 2015; 36:603–10.
Article
22. Takuma Y, Nouso K, Morimoto Y, Tomokuni J, Sahara A, Takabatake H, et al. Portal hypertension in patients with liver cirrhosis: diagnostic accuracy of spleen stiffness. Radiology. 2016; 279:609–19.
Article
23. Salzl P, Reiberger T, Ferlitsch M, Payer BA, Schwengerer B, Trauner M, et al. Evaluation of portal hypertension and varices by acoustic radiation force impulse imaging of the liver compared to transient elastography and AST to platelet ratio index. Ultraschall Med. 2014; 35:528–33.
Article
24. Hai Y, Chong W, Eisenbrey JR, Forsberg F. Network meta-analysis: noninvasive imaging modalities for identifying clinically significant portal hypertension. Dig Dis Sci. 2021; Jul. 17. [Epub].
https://doi.org/10.1007/s10620-021-07168-y.
Article
25. Lin ZH, Xin YN, Dong QJ, Wang Q, Jiang XJ, Zhan SH, et al. Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis. Hepatology. 2011; 53:726–36.
Article